conclusions our study showed that microrelin is as effective as diphereline in reducing psa and testosterone and can be recommended to initiate medical castration in patients with pc. results each group contained 40 patients. in group a, psa was reduced from 75.78 ± 72.43 ng/ml to 1.93 ± 1.40 ng/ml after 6 months and testosterone was reduced from 3.50 ± 1.12 nmol/l to 0.81 ± 0.05 nmol/l. there ...

OBJECTIVES The objective of this study was to assess differences in efficacy outcomes between luteinizing hormone-releasing hormone (LHRH) agonist plus antiandrogen (AA) flare protection and monotherapy with the gonadotrophin-releasing hormone antagonist degarelix in patients with prostate cancer. METHODS Data from 1455 patients were pooled from two prospective, phase III randomized 1-year cl...

Pituitary stimulation with pulsatile gonadotropin-releasing hormone (GnRH) analogs induces both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Pituitary gonadotropin secretions are blocked upon desensitization when a continuous GnRH stimulus is provided by means of an agonist or when the pituitary receptors are occupied with a competitive antagonist. GnRH antagonists were not ...

Kung et al authored a valuable article entitled “Luteal phase support with decapeptyl improves pregnancy outcomes in ICSI with basal FSH >8 mIU/mL or mature oocytes 3”. This retrospective study enrolled 240 patients who underwent intracytoplasmic sperm injection (ICSI). One hundred and forty-seven patients were in the decapeptyl group and 93 patients were in the control group. The authors inves...

treatment of central precocious puberty (cpp) is the administration of gnrh analogs. metabolic syndrome comprised metabolic disturbances that confer increased risk of (cvd) diabetes mellitus (dm) and cardiovascular disease. this study is a longitudinal prospective study in pediatric endocrinology clinic. 30 non-obese children with idiopathic cpp were involved. total body weight, height, blood p...

Westergaard LG, Yding Andersen C. GnRH agonist (Buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomised study. Hum Reprod 2005; 20:1213–1220. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory hCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agoni...

This study explored the effects of GnRH agonist (GnRHa) immunity on expression of FSHR mRNA in pituitary and FSHR protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups (EG) during anestrus season. Animals in EG-I, EG-II and EG-III were subcutaneously injected with 200, 300 and 400 μg alarelin antigens (...

BACKGROUND Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. A concern about these drugs is obesity. OBJECTIVES This study aimed to investigate the effect of gonadotropin-releasing hormone agonists (GnRHa) therapy on body mass index (BMI) in girls with central precocious puberty (CPP). PATIENTS ...